Sath assumed the role of Chief Financial Officer of the organization on August 29, 2023. Prior to that, he was the Chief Financial Officer for Europe, the Middle East, and Africa at Prenetics, a prominent health sciences company driven by genomics. With over fifteen years of experience in the healthcare industry, he has held positions at Reckitt and BTG, among other FTSE and NASDAQ-listed companies. Before this, Sath held investment banking positions at both Nomura and KPMG. Sath holds the Chartered Accountant designation and is an active member of the Institute of Chartered Accountants in England and Wales. Additionally, Sath serves on The Institute of Cancer Research’s audit committee as a Non-Executive Member. A BSc in Pharmacology was bestowed upon him by King’s College, London.
Regarding Scancel
Scancell, a biopharmaceutical company in the clinical stage, is applying its proprietary knowledge gained from years of studying the human adaptive immune system to develop innovative treatments for infectious disease and cancer that currently have substantial unmet medical requirements. The organization is constructing a series of groundbreaking products through the application of its four technological platforms: GlyMab® and AvidiMab® for antibodies; and Moditope® and ImmunoBody® for vaccines.
Adaptive immune responses comprise T cells and antibodies, both of which are capable of identifying compromised or infected cells. Scancell utilizes monoclonal antibodies to redirect immune cells or medications, as well as vaccines to stimulate immune responses, in order to eliminate these cancerous or infected cells. Unique to the organization is the fact that its cutting-edge products specifically target lipid and protein modifications. This includes homocitrullination and citrullination of proteins for the vaccines, whereas its mAb portfolio enhances the potency of antibodies and their capacity to directly destroy tumor cells or targets glycans or sugars that are added to proteins and/or lipids.
